Figure 4.
CD8 T cells are critical for the synergistic effects of BO-112 and DMXAA intratumoral co-injections. MC38 tumor-bearing mice were treated as described in figure 1A. Mice received intraperitoneal injections of rat IgG, anti-NK1.1, anti-CD8β or anti-CD4 to deplete NK/NKT, CD8 and/or CD4 T cells respectively as color coded in the graphs. (A) The mean (±SEM) of tumor size (mm3) is shown for treated (left panel) and untreated (right panel) tumors. (B) The percentage of surviving mice is shown over time. Data are representative of two independent experiments with six mice per group (mean±SEM). Two-way analyses of variance (ANOVAs) (A) or log-rank (B) test were used to assess significance. Significant differences are displayed for comparisons of each group with BO-112 +DMXAA group without depletion (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). DMXAA, 5,6-dimethylxanthenone-4-acetic acid.